Registry and Biosample Repository

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2015 by Abramson Cancer Center of the University of Pennsylvania
Sponsor:
Information provided by (Responsible Party):
Abramson Cancer Center of the University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT01577251
First received: April 12, 2012
Last updated: December 8, 2015
Last verified: December 2015
  Purpose
The goal of this study is two-fold: to establish a tissue banking respository (defined as blood, urine, soft tissue, tumor specimen, and normal tissue from areas surrounding tumor specimens), and to prospectively assess health related quality of life (QOL) over time in patients with a pathologically confirmed diagnosis of neoplasia receiving radiotherapy or photodynamic therapy (PDT)

Condition
Patients With Pathologically Confirmed Neoplasia That Have Been
Selected for Definitive Photodynamic Therapy, Proton, or Photon
Radiotherapy.

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Registry and Biosample Repository

Further study details as provided by Abramson Cancer Center of the University of Pennsylvania:

Primary Outcome Measures:
  • Health Assessments [ Time Frame: 10 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 2500
Study Start Date: June 2008
Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 89 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Donors will be between the ages of 18 and 89 with pathologically confirmed neoplasia that are selected for definitive photodynamic therapy, proton, photon radiotherapy

-Pediatric patients with pathologically confirmed neoplasia that have been selected for definitive radiotherapy may elect to participate in a pediatric arm of quality of life, provided that the proper processes of parental permission and assent have occurred.

Criteria

Inclusion Criteria:

  • Anyone age 18 and above with a cancer diagnosis
  • Able to sign consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01577251

Contacts
Contact: Jay Dorsey, MD, PhD 855-216-0098 PennCancerTrials@emergingmed.com
Contact: Susan Mazzoni 215-662-6083 susan.mazzoni@uphs.upenn.edu

Locations
United States, Pennsylvania
Abramson Cancer Center of the University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19004
Contact: Jay Dorsey, MD, PhD    855-216-0098    PennCancerTrials@emergingmed.com   
Principal Investigator: Jay Dorsey, MD, PhD         
Sponsors and Collaborators
Abramson Cancer Center of the University of Pennsylvania
Investigators
Principal Investigator: Jay Dorsey, MD, PhD Abramson Cancer Center of the University of Pennsylvania
  More Information

Responsible Party: Abramson Cancer Center of the University of Pennsylvania
ClinicalTrials.gov Identifier: NCT01577251     History of Changes
Other Study ID Numbers: UPCC 11908 
Study First Received: April 12, 2012
Last Updated: December 8, 2015
Health Authority: United States: Institutional Review Board

ClinicalTrials.gov processed this record on July 21, 2016